These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 30400103

  • 1. Disease Progression in Huntington Disease: An Analysis of Multiple Longitudinal Outcomes.
    Garcia TP, Wang Y, Shoulson I, Paulsen JS, Marder K.
    J Huntingtons Dis; 2018; 7(4):337-344. PubMed ID: 30400103
    [Abstract] [Full Text] [Related]

  • 2. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
    Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C.
    JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
    [Abstract] [Full Text] [Related]

  • 3. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.
    Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, Shoulson I.
    Neurology; 2013 May 28; 80(22):2022-7. PubMed ID: 23624566
    [Abstract] [Full Text] [Related]

  • 4. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.
    Paulsen JS, Long JD, Ross CA, Harrington DL, Erwin CJ, Williams JK, Westervelt HJ, Johnson HJ, Aylward EH, Zhang Y, Bockholt HJ, Barker RA, PREDICT-HD Investigators and Coordinators of the Huntington Study Group.
    Lancet Neurol; 2014 Dec 28; 13(12):1193-201. PubMed ID: 25453459
    [Abstract] [Full Text] [Related]

  • 5. Rate of functional decline in Huntington's disease. Huntington Study Group.
    Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I.
    Neurology; 2000 Jan 25; 54(2):452-8. PubMed ID: 10668713
    [Abstract] [Full Text] [Related]

  • 6. Clinical manifestations of intermediate allele carriers in Huntington disease.
    Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C, European HD Network.
    Neurology; 2016 Aug 09; 87(6):571-8. PubMed ID: 27402890
    [Abstract] [Full Text] [Related]

  • 7. The relationship between CAG repeat length and clinical progression in Huntington's disease.
    Ravina B, Romer M, Constantinescu R, Biglan K, Brocht A, Kieburtz K, Shoulson I, McDermott MP.
    Mov Disord; 2008 Jul 15; 23(9):1223-7. PubMed ID: 18512767
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR, TRACK-HD investigators.
    Lancet Neurol; 2012 Jan 15; 11(1):42-53. PubMed ID: 22137354
    [Abstract] [Full Text] [Related]

  • 10. Clinical manifestations of homozygote allele carriers in Huntington disease.
    Cubo E, Martinez-Horta SI, Santalo FS, Descalls AM, Calvo S, Gil-Polo C, Muñoz I, Llano K, Mariscal N, Diaz D, Gutierrez A, Aguado L, Ramos-Arroyo MA, European HD Network.
    Neurology; 2019 Apr 30; 92(18):e2101-e2108. PubMed ID: 30867264
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR, TRACK-HD Investigators.
    Lancet Neurol; 2013 Jul 30; 12(7):637-49. PubMed ID: 23664844
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Preparing for preventive clinical trials: the Predict-HD study.
    Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E, Predict-HD Investigators of the Huntington Study Group.
    Arch Neurol; 2006 Jun 30; 63(6):883-90. PubMed ID: 16769871
    [Abstract] [Full Text] [Related]

  • 16. Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.
    Fusilli C, Migliore S, Mazza T, Consoli F, De Luca A, Barbagallo G, Ciammola A, Gatto EM, Cesarini M, Etcheverry JL, Parisi V, Al-Oraimi M, Al-Harrasi S, Al-Salmi Q, Marano M, Vonsattel JG, Sabatini U, Landwehrmeyer GB, Squitieri F.
    Lancet Neurol; 2018 Nov 30; 17(11):986-993. PubMed ID: 30243861
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Exploring the correlates of intermediate CAG repeats in Huntington disease.
    Ha AD, Jankovic J.
    Postgrad Med; 2011 Sep 30; 123(5):116-21. PubMed ID: 21904093
    [Abstract] [Full Text] [Related]

  • 19. Severity of cognitive impairment in juvenile and late-onset Huntington disease.
    Gómez-Tortosa E, del Barrio A, García Ruiz PJ, Pernaute RS, Benítez J, Barroso A, Jiménez FJ, García Yébenes J.
    Arch Neurol; 1998 Jun 30; 55(6):835-43. PubMed ID: 9626775
    [Abstract] [Full Text] [Related]

  • 20. Weight loss in Huntington disease increases with higher CAG repeat number.
    Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, EHDI Study Group, Roos RA.
    Neurology; 2008 Nov 04; 71(19):1506-13. PubMed ID: 18981372
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.